Search
- Report
Chapin White, CBO's Director of Health Analysis, testifies before the House Energy and Commerce Committee's Subcommittee on Health.
- Cost Estimate
As reported by the Senate Committee on Health, Education, Labor, and Pensions on October 4, 2023
- Cost Estimate
As reported by the Senate Committee on Health, Education, Labor, and Pensions on October 4, 2023
- Cost Estimate
As reported by the Senate Committee on Health, Education, Labor, and Pensions on July 27, 2023
- Cost Estimate
As reported by the Senate Committee on Health, Education, Labor, and Pensions on July 27, 2023
- Cost Estimate
As reported by the House Committee on Energy and Commerce on August 25, 2023
- Report
In response to a request from Budget Committee Chairman Jodey Arrington and Congressman Michael C. Burgess, CBO provides information about its analysis of federal policies that affect the development of new drugs in the United States.
- Blog Post
To enhance its work for the Congress, CBO is looking for new research that examines how changes in pharmaceutical companies’ expected future profits affect the development of new drugs and health outcomes.
- Cost Estimate
As reported by the Senate Committee on Health, Education, Labor, and Pensions on July 26, 2023
- Cost Estimate
As introduced on July 25, 2023